Who
Norman D. Schwartz
Chairman & CEO
Company insider
Files Form 4 as: Chairman & CEO, Bio-Rad Laboratories.
In numbers
- Trades disclosed
- 363
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $700K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Feb 2002
- Last trade
- 6 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —3,455 at $0.00 | filing |
| 6 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —3,455 at $0.00 | filing |
| 6 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $716K1,854 at $386.11 | filing |
| 6 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —3,455 at $0.00 | filing |
| 6 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —3,455 at $0.00 | filing |
| 6 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $716K1,854 at $386.11 | filing |
| 5 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —4,109 at $0.00 | filing |
| 5 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $1.1M2,876 at $386.11 | filing |
| 5 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —4,109 at $0.00 | filing |
| 5 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —4,109 at $0.00 | filing |
| 5 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —4,109 at $0.00 | filing |
| 5 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $1.1M2,876 at $386.11 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code A | —17,251 at $0.00 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code A | —17,251 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code M | —5,087 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | BIO Bio-Rad LaboratoriesLife-science tools | SEC FORM 4 Code F | $890K2,336 at $380.96 | filing |
| 1 Sep 2026filed 3 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —2,082 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —2,082 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —3,005 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | BIO Bio-Rad Laboratoriesoption or derivative · Life-science tools | SEC FORM 4 Code M | —3,005 at $0.00 | filing |
News
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Recommendation of "Hold" from BrokeragesBIO · themarketsdaily.com · 7 Oct 2026
0 headlines in the last 90 days name Norman D. Schwartz; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.